OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: AMEX:OCX
- CUSIP: N/A
- Web: www.oncocyte.com/
- 50 Day Moving Avg: $6.26
- 200 Day Moving Avg: $6.26
- 52 Week Range: $3.75 - $7.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -12.22
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.19 per share
- Price / Book: 34.74
- EBIDTA: ($13,320,000.00)
- Return on Equity: -211.74%
- Return on Assets: -111.72%
- Average Volume: 47,057 shs.
- Short Ratio: 5.79
Frequently Asked Questions for OncoCyte Corp (AMEX:OCX)
What is OncoCyte Corp's stock symbol?
OncoCyte Corp trades on the AMEX under the ticker symbol "OCX."
Where is OncoCyte Corp's stock going? Where will OncoCyte Corp's stock price be in 2017?
2 equities research analysts have issued 12 month price targets for OncoCyte Corp's shares. Their predictions range from $7.75 to $7.75. On average, they expect OncoCyte Corp's stock price to reach $7.75 in the next twelve months. View Analyst Ratings for OncoCyte Corp.
Who are some of OncoCyte Corp's key competitors?
Some companies that are related to OncoCyte Corp include Mersana Therapeutics (MRSN), UROGEN PHARMA (URGN), Bellicum Pharmaceuticals (BLCM), Merus N.V. (MRUS), Corbus Pharmaceuticals Holdings (CRBP), Geron Corporation (GERN), Kura Oncology (KURA), BioSpecifics Technologies Corp (BSTC), Ra Pharmctl (RARX), CymaBay Therapeutics (CBAY), BioTime (BTX), Edge Therapeutics (EDGE), Rigel Pharmaceuticals (RIGL), Minerva Neurosciences (NERV), Athersys (ATHX), Stemline Therapeutics (STML), Forward Pharma A/S (FWP) and Oxford BioMedica plc (OXB).
How do I buy OncoCyte Corp stock?
Shares of OncoCyte Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoCyte Corp's stock price today?
MarketBeat Community Rating for OncoCyte Corp (AMEX OCX)MarketBeat's community ratings are surveys of what our community members think about OncoCyte Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of OncoCyte Corp stock can currently be purchased for approximately $6.60.
Consensus Ratings for OncoCyte Corp (AMEX:OCX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$7.75|
Analysts' Ratings History for OncoCyte Corp (AMEX:OCX)
(Data available from 9/26/2015 forward)
|5/23/2017||Chardan Capital||Boost Price Target||Buy||$6.50 -> $7.75|
|1/30/2017||Canaccord Genuity||Reiterated Rating||Buy|
Earnings History for OncoCyte Corp (AMEX:OCX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for OncoCyte Corp (AMEX:OCX)
2017 EPS Consensus Estimate: ($0.38)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for OncoCyte Corp (AMEX:OCX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for OncoCyte Corp (AMEX:OCX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for OncoCyte Corp (AMEX:OCX)
Latest Headlines for OncoCyte Corp (AMEX:OCX)